Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Return on Sales (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Return on Sales for 15 consecutive years, with 0.19% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales rose 3.0% year-over-year to 0.19%, compared with a TTM value of 0.17% through Dec 2025, up 2.0%, and an annual FY2025 reading of 0.17%, up 2.0% over the prior year.
  • Return on Sales was 0.19% for Q4 2025 at Neurocrine Biosciences, down from 0.26% in the prior quarter.
  • Across five years, Return on Sales topped out at 2.82% in Q2 2021 and bottomed at 0.18% in Q1 2023.
  • Average Return on Sales over 4 years is 0.32%, with a median of 0.16% recorded in 2024.
  • The sharpest move saw Return on Sales soared 256bps in 2021, then dropped -16bps in 2024.
  • Year by year, Return on Sales stood at 0.1% in 2021, then skyrocketed by 153bps to 0.26% in 2023, then plummeted by -37bps to 0.16% in 2024, then rose by 16bps to 0.19% in 2025.
  • Business Quant data shows Return on Sales for NBIX at 0.19% in Q4 2025, 0.26% in Q3 2025, and 0.16% in Q2 2025.